Sequential Dendritic Cell Vaccination After Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dendritic cell (DC) vaccines administered in parallel with chemotherapy demonstrate poor therapeutic efficacy due to sub-optimal immune system recovery post-chemotherapy, limited immunogenicity of tumor-associated antigens (TAAs), and challenges in DC localization, leading to limited clinical benefits for cancer patients.
Innovation Solution
Administering a DC vaccine sequentially after completion of chemotherapy, loaded with tumor-associated antigens and matured with Toll-like receptor agonists, to enhance immune response and improve overall survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is administered to treat cancer, then tumor cells are killed, but the immune system becomes suppressed and cannot effectively fight remaining cancer cells
Solution Approach 1:
The patent applies preliminary action by administering dendritic cell vaccination before chemotherapy treatment. The dendritic cells are prepared ex vivo and infused into the patient prior to chemotherapy, establishing an immune framework that can respond to tumor antigens before the chemotherapy-induced immune suppression occurs. This timing allows the immune system to be primed in advance to combat cancer cells during and after chemotherapy.
Solution Approach 2:
The dendritic cells serve as an intermediary between the chemotherapy treatment and the immune system. These cells are engineered to express tumor antigens and co-stimulatory molecules, acting as a bridge that translates chemotherapy-induced tumor cell death into effective immune responses. The dendritic cells mediate the interaction between the cytotoxic chemotherapy agents and the patient's immune system, converting a potentially harmful side effect into a therapeutic opportunity.
2Productivity
If high doses of chemotherapy are used to maximize cancer cell killing, then tumor response improves, but normal cells are damaged and immune function is further suppressed
Solution Approach 1:
The patent converts the harmful side effect of chemotherapy-induced immune suppression into a beneficial effect. By administering dendritic cell vaccines that express tumor antigens, the treatment transforms the immunosuppressed state into an opportunity for targeted immune activation against cancer cells. The chemotherapy-induced release of tumor antigens, which would normally be harmful by suppressing immunity, is instead harnessed to enhance the specificity and effectiveness of the dendritic cell vaccine.
3Reliability
If dendritic cell vaccination is administered before chemotherapy, then immune system is primed to fight cancer, but the timing and coordination of treatments becomes complex
Solution Approach 1:
The patent applies segmentation by dividing the treatment into distinct phases: (1) dendritic cell preparation and infusion, (2) chemotherapy administration, and (3) follow-up immune monitoring. This segmentation allows each component to be optimized independently while maintaining overall coordination. The dendritic cell vaccine is administered as a separate, discrete intervention that can be scheduled relative to chemotherapy cycles, reducing the complexity of simultaneous multi-modal treatment.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the use of a dendritic cell vaccination sequential to chemotherapy, wherein the dendritic cell vaccine is administered to a patient after completion of chemotherapy with at least one chemotherapeutic agent.